This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singh, R. P. Articles by Agarwal, R. Search for Related Content PubMed PubMed Citation Articles by Singh, R. P. Articles by Agarwal, R.

Suppression of Advanced Human Prostate Tumor Growth in Athymic Mice by Silibinin Feeding Is Associated with Reduced Cell Proliferation, Increased Apoptosis, and Inhibition of Angiogenesis¹

Department of Pharmaceutical Sciences, School of Pharmacy [R. P. S., G. S., S. D., C. A., R. A.], University of Colorado Cancer Center [R. A.], University of Colorado Health Sciences Center, Denver, Colorado 80262

Recently, we observed that dietary feeding of silibinin strongly prevents and inhibits the growth of advanced human prostate tumor xenografts in athymic nude mice without any apparent signs of toxicity together with increased secretion of insulin-like growth factor-binding protein 3 from the tumor in to mouse plasma (R. P. Singh et al., Cancer Res., 62: 3063–3069, 2002). In the present study, we investigated the effect of silibinin feeding [0.05% and 0.1% (w/w) in diet for 60 days] on the prognostic biomarkers (namely, proliferation, apoptosis, and angiogenesis) in the prostate tumor xenografts of the above-reported study. Immunohistochemical analysis of the tumors for proliferating cell nuclear antigen and Ki-67 showed that silibinin decreases proliferation index by 28–60% and 30–60% (P < 0.001) as compared with their controls, respectively. In situ detection of apoptosis by terminal deoxynucleotidyl transferase dUTP-mediated nick end labeling staining of tumors showed a 7.4–8.1-fold (P < 0.001) increase in apoptotic cells in silibinin-fed groups over that of control group. Silibinin also increased activated caspase 3-positive cells by 2.3–3.6-fold (P < 0.001). CD31 staining for tumor vasculature showed a significant decrease (21–38%; P < 0.001) in tumor microvessel density in silibinin-fed groups of tumors as compared with control group of tumors. Tumor sections were also analyzed for vascular endothelial growth factor and insulin-like growth factor-binding protein 3 protein expression, and a slightly decreased and a moderately increased cytoplasmic immunostaining in silibinin-fed groups were observed as compared with the control group, respectively. Together, these results suggest that inhibition of advanced human prostate tumor xenograft growth in athymic nude mice by silibinin is associated with its in vivo antiproliferative, proapoptotic, and antiangiogenic efficacy in prostate tumor.

This article has been cited by other articles:

				S. Zanardi, M. Puntoni, M. Maffezzini, R. Bandelloni, M. Mori, A. Argusti, F. Campodonico, L. Turbino, D. Branchi, R. Montironi, et al. Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies Cancer Prevention Research, April 1, 2009; 2(4): 377 - 384. [Abstract] [Full Text] [PDF]

				R. P. Singh, K. Raina, G. Deep, D. Chan, and R. Agarwal Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3 Orthotopic Xenograft via Activation of Extracellular Signal-Regulated Kinase 1/2 and Inhibition of Signal Transducers and Activators of Transcription Signaling Clin. Cancer Res., January 15, 2009; 15(2): 613 - 621. [Abstract] [Full Text] [PDF]

				B. Velmurugan, R. P. Singh, A. Tyagi, and R. Agarwal Inhibition of Azoxymethane-Induced Colonic Aberrant Crypt Foci Formation by Silibinin in Male Fisher 344 Rats Cancer Prevention Research, October 1, 2008; 1(5): 376 - 384. [Abstract] [Full Text] [PDF]

				K. Raina, S. Rajamanickam, R. P. Singh, G. Deep, M. Chittezhath, and R. Agarwal Stage-Specific Inhibitory Effects and Associated Mechanisms of Silibinin on Tumor Progression and Metastasis in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., August 15, 2008; 68(16): 6822 - 6830. [Abstract] [Full Text] [PDF]

				K. Raina, S. Rajamanickam, R. P. Singh, and R. Agarwal Chemopreventive Efficacy of Inositol Hexaphosphate against Prostate Tumor Growth and Progression in TRAMP Mice Clin. Cancer Res., May 15, 2008; 14(10): 3177 - 3184. [Abstract] [Full Text] [PDF]

				K. Raina, S. Rajamanickam, G. Deep, M. Singh, R. Agarwal, and C. Agarwal Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice Mol. Cancer Ther., May 1, 2008; 7(5): 1258 - 1267. [Abstract] [Full Text] [PDF]

				R. P. Singh, M. Gu, and R. Agarwal Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis Cancer Res., March 15, 2008; 68(6): 2043 - 2050. [Abstract] [Full Text] [PDF]

				R. P. Singh, A. Tyagi, G. Sharma, S. Mohan, and R. Agarwal Oral Silibinin Inhibits In vivo Human Bladder Tumor Xenograft Growth Involving Down-Regulation of Survivin Clin. Cancer Res., January 1, 2008; 14(1): 300 - 308. [Abstract] [Full Text] [PDF]

				R. P. Singh, G. Deep, M.-J. Blouin, M. N. Pollak, and R. Agarwal Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft Carcinogenesis, December 1, 2007; 28(12): 2567 - 2574. [Abstract] [Full Text] [PDF]

				K. Raina, M.-J. Blouin, R. P. Singh, N. Majeed, G. Deep, L. Varghese, L. M. Glode, N. M. Greenberg, D. Hwang, P. Cohen, et al. Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., November 15, 2007; 67(22): 11083 - 11091. [Abstract] [Full Text] [PDF]

				G. Deep and R. Agarwal Chemopreventive Efficacy of Silymarin in Skin and Prostate Cancer Integr Cancer Ther, June 1, 2007; 6(2): 130 - 145. [Abstract] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]

				M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]

				D. R. Yance Jr and S. M. Sagar Targeting Angiogenesis With Integrative Cancer Therapies Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF]

				M. F. McCarty and K. I. Block Multifocal Angiostatic Therapy: An Update Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314. [Abstract] [PDF]

				B. Liu, K.-W. Lee, H. Li, L. Ma, G. L. Lin, R. A.S. Chandraratna, and P. Cohen Combination Therapy of Insulin-Like Growth Factor Binding Protein-3 and Retinoid X Receptor Ligands Synergize on Prostate Cancer Cell Apoptosis In vitro and In vivo Clin. Cancer Res., July 1, 2005; 11(13): 4851 - 4856. [Abstract] [Full Text] [PDF]

				H. Kohno, R. Suzuki, S. Sugie, H. Tsuda, and T. Tanaka Dietary Supplementation with Silymarin Inhibits 3,2'-Dimethyl-4-Aminobiphenyl-Induced Prostate Carcinogenesis in Male F344 Rats Clin. Cancer Res., July 1, 2005; 11(13): 4962 - 4967. [Abstract] [Full Text] [PDF]

				R. P. Singh, G. U. Mallikarjuna, G. Sharma, S. Dhanalakshmi, A. K. Tyagi, D. C. F. Chan, C. Agarwal, and R. Agarwal Oral Silibinin Inhibits Lung Tumor Growth in Athymic Nude Mice and Forms a Novel Chemocombination with Doxorubicin Targeting Nuclear Factor {kappa}B-Mediated Inducible Chemoresistance Clin. Cancer Res., December 15, 2004; 10(24): 8641 - 8647. [Abstract] [Full Text] [PDF]

				M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]

				H. J. Thompson, J. N. McGinley, P. Wolfe, N. S. Spoelstra, and K. K. Knott Targeting Angiogenesis for Mammary Cancer Prevention: Factors to Consider in Experimental Design and Analysis Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1173 - 1184. [Abstract] [Full Text] [PDF]

				R. P. Singh, G. Sharma, G. U. Mallikarjuna, S. Dhanalakshmi, C. Agarwal, and R. Agarwal In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate: Induction of Insulin-Like Growth Factor Binding Protein-3 and Inhibition of Vascular Endothelial Growth Factor Clin. Cancer Res., January 1, 2004; 10(1): 244 - 250. [Abstract] [Full Text] [PDF]